China Approves Hisun Pharmaceutical's Aspergillosis Tablets

MT Newswires Live09-27

China's medical products administrator granted Zhejiang Hisun Pharmaceutical (SHA:600267) drug registration approval for its posaconazole enteric-coated tablets for invasive aspergillosis in adult patients, according to a Friday filing with the Shanghai Stock Exchange.

The drug is indicated for patients 13 years old and above with a higher risk for invasive aspergillus and candida infections who have low immunity due to graft-versus-host disease after stem cell transplants or low white blood cell count following chemotherapy, the filing said.

Shares closed 4% during Friday's afternoon trading.

Price (RMB): Â¥7.94, Change: Â¥+0.31, Percent Change: +4.06%

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2470085037?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-09-27 18:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2470085037","market":"sg","top_or_hot":-1,"title":"China Approves Hisun Pharmaceutical's Aspergillosis Tablets","media":"MT Newswires Live","content":"<html><body><p> China's medical products administrator granted Zhejiang Hisun Pharmaceutical (SHA:600267) drug registration approval for its posaconazole enteric-coated tablets for invasive aspergillosis in adult patients, according to a Friday filing with the Shanghai Stock Exchange.</p><p>The drug is indicated for patients 13 years old and above with a higher risk for invasive aspergillus and candida infections who have low immunity due to graft-versus-host disease after stem cell transplants or low white blood cell count following chemotherapy, the filing said.</p><p>Shares closed 4% during Friday's afternoon trading.</p><p>Price (RMB): Â¥7.94, Change: Â¥+0.31, Percent Change: +4.06%</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>China Approves Hisun Pharmaceutical's Aspergillosis Tablets</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChina Approves Hisun Pharmaceutical's Aspergillosis Tablets\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-27 18:10 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>China's medical products administrator granted Zhejiang Hisun Pharmaceutical (SHA:600267) drug registration approval for its posaconazole enteric-coated tablets for invasive aspergillosis in adult ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0188","symbol_name":"融资融券","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2470085037","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2470085037","pubTimestamp":1727431838,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"China's medical products administrator granted Zhejiang Hisun Pharmaceutical  drug registration approval for its posaconazole enteric-coated tablets for invasive aspergillosis in adult patients, according to a Friday filing with the Shanghai Stock Exchange.The drug is indicated for patients 13 years old and above with a higher risk for invasive aspergillus and candida infections who have low immunity due to graft-versus-host disease after stem cell transplants or low white blood cell count following chemotherapy, the filing said.Shares closed 4% during Friday's afternoon trading.Price : 7.94, Change: +0.31, Percent Change: +4.06%","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600267":"海正药业","BK0188":"融资融券","BK0028":"国家队","BK0060":"抗癌","BK0239":"医药制造"},"translate_title":"中国批准海正药业曲霉菌病片","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600267":0.9},"content_text":"China's medical products administrator granted Zhejiang Hisun Pharmaceutical (SHA:600267) drug registration approval for its posaconazole enteric-coated tablets for invasive aspergillosis in adult patients, according to a Friday filing with the Shanghai Stock Exchange.The drug is indicated for patients 13 years old and above with a higher risk for invasive aspergillus and candida infections who have low immunity due to graft-versus-host disease after stem cell transplants or low white blood cell count following chemotherapy, the filing said.Shares closed 4% during Friday's afternoon trading.Price (RMB): Â¥7.94, Change: Â¥+0.31, Percent Change: +4.06%","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2470085037"}